Microbot Medical Schedules Virtual Meeting to Address Increased Interest Following its Recent Announcement
August 20 2020 - 10:00AM
Following its participation at the Needham Virtual Med Tech &
Diagnostic conference, as well as the overwhelming interest
generated since its recent announcement which included the outcome
of a feasibility animal study with respect to the LIBERTYTM Robotic
System, Microbot Medical Inc. (Nasdaq: MBOT) will host a webinar on
Wednesday, August 26, 2020 at 11:00am ET. Harel Gadot, the
Company’s CEO, President and Chairman, will share the Company’s
view on the surgical robotic market, the results of the feasibility
animal study, as well as other recent achievements. Additionally,
members of the Company’s management team, including Dr. Eyal Morag,
Chief Medical Officer, Simon Sharon, Chief Technology Officer and
Eran Cohen, Senior Director of Business Development, will be
available for a question and answer session.
To participate on the webinar, please register
in advance at:
https://zoom.us/webinar/register/WN_5JfsfM-aR4WVKdJncgGbvw. After
registering, participants will receive a confirmation email
containing information about joining the webinar.
The LIBERTYTM Robotic System, which the Company
believes to be the first fully disposable surgical robotic system,
has met all of its end points with no intraoperative adverse
events. This supports the Company’s vision of democratizing
endoluminal procedures while enhancing clinical and economical
outcomes. The LIBERTYTM Robotic System has the potential to
allow physicians to conduct catheter-based procedure from
outside the catheterization laboratory (cath-lab), avoiding
radiation exposure, physical strain and the risk of cross
contamination. The study was performed by two leading
physicians in the neuro vascular and peripheral vascular
intervention spaces, and the results demonstrated robust navigation
capabilities, intuitive usability and accurate deployment of
embolic agents, most of which was conducted remotely from the
cath-lab’s control room.
About Microbot Medical
Microbot Medical Inc. (NASDAQ: MBOT) is a
pre-clinical medical device company that specializes in
transformational micro-robotic technologies, focused primarily on
both natural and artificial lumens within the human body.
Microbot’s current proprietary technological platforms provide the
foundation for the development of a Multi Generation Pipeline
Portfolio (MGPP).
Microbot Medical was founded in 2010 by Harel
Gadot, Prof. Moshe Shoham, and Yossi Bornstein with the goals of
improving clinical outcomes for patients and increasing
accessibility through the use of micro-robotic technologies.
Further information about Microbot Medical is available at
http://www.microbotmedical.com.
Safe Harbor
Statements pertaining to the registered direct
offering, timing, the amount and anticipated use of proceeds and
statements pertaining to future financial and/or operating results,
future growth in research, technology, clinical development, and
potential opportunities for Microbot Medical Inc. and its
subsidiaries, along with other statements about the future
expectations, beliefs, goals, plans, or prospects expressed by
management, constitute forward-looking statements within the
meaning of the Private Securities Litigation Reform Act of 1995 and
the Federal securities laws. Any statements that are not historical
fact (including, but not limited to statements that contain words
such as “will,” “believes,” “plans,” “anticipates,” “expects” and
“estimates”) should also be considered to be forward-looking
statements. Forward-looking statements involve risks and
uncertainties, including, without limitation, market conditions and
the satisfaction of customary closing conditions, risks inherent in
the development and/or commercialization of potential products,
including LIBERTYTM, the outcome of its studies to evaluate the SCS
and other existing and future technologies, uncertainty in the
results of pre-clinical and clinical trials or regulatory pathways
and regulatory approvals, uncertainty resulting from the COVID-19
pandemic, need and ability to obtain future capital, and
maintenance of intellectual property rights. Additional information
on risks facing Microbot Medical can be found under the heading
“Risk Factors” in Microbot Medical’s periodic reports filed with
the Securities and Exchange Commission (SEC) and in the prospectus
supplement related to the registered direct offering to be filed
with the SEC, which are or will be available on the SEC’s web site
at www.sec.gov. Microbot Medical disclaims any intent or obligation
to update these forward-looking statements, except as required by
law.
Investor Contact:
Michael PolyviouEVC Groupmpolyviou@evcgroup.com732-933-2754
Microbot Medical (NASDAQ:MBOT)
Historical Stock Chart
From Aug 2024 to Sep 2024
Microbot Medical (NASDAQ:MBOT)
Historical Stock Chart
From Sep 2023 to Sep 2024